Actively Recruiting
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.
Led by AstraZeneca · Updated on 2026-04-27
104
Participants Needed
2
Research Sites
81 weeks
Total Duration
On this page
Sponsors
A
AstraZeneca
Lead Sponsor
P
Parexel
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of the study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD1043 following single and multiple ascending doses in healthy adult participants living with overweight and/or obesity, including participants of Japanese and Chinese descent.
CONDITIONS
Official Title
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- All female participants must have a negative pregnancy test at screening and upon admission.
- Female participants must be of non-childbearing potential, confirmed postmenopausal or surgically sterilized.
- Body mass index must be between 25 and 39.9 kg/m2 for global cohorts or between 23 and 39.9 kg/m2 for Japanese and Chinese cohorts.
- Participants must weigh at least 50 kg.
- Japanese participants must have both parents and four grandparents of Japanese descent, including second and third generations.
- Chinese participants must have both parents and four grandparents of Chinese ethnicity, including second and third generations.
You will not qualify if you...
- History of any clinically important disease or disorder.
- History or presence of gastrointestinal, liver, or kidney disease or any condition affecting drug absorption, distribution, metabolism, or excretion.
- Any significant illness, surgery, or trauma within 4 weeks before starting the study drug.
- Clinically important abnormal laboratory values or vital signs.
- History of severe allergies or ongoing allergies to drugs similar to AZD1043.
- Use of any weight loss medications within 3 months before screening.
- History of psychosis, bipolar disorder, or unstable major depressive disorder within the past 2 years.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Research Site
Glendale, California, United States, 91206
Actively Recruiting
2
Research Site
Harrow, United Kingdom, HA1 3UJ
Not Yet Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
13
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here